Invitae Corp (NVTA) |
|
39.49 -2.6 (-6.18%)
|
02-25 12:17 |
|
Open: |
41.6 |
Pre. Close: |
42.09 |
|
High:
|
42.35 |
Low:
|
39.27 |
|
Volume:
|
1,995,389 |
Market Cap:
|
7,528M |
|
|
|
|
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children; and a research collaboration with Pacific Biosciences of California, Inc. for the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
44.008 - 44.367 |
44.367 - 44.608 |
|
Low:
|
40.172 - 40.548 |
40.548 - 40.801 |
|
Close:
|
41.586 - 42.182 |
42.182 - 42.582 |
|
Technical analysis |
as of: 2021-02-25 11:49:07 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 58.46  One year: 67.16 |
| Support: |
Support1: 38.00 Support2: 31.62 |
| Resistance: |
Resistance1: 50.05 Resistance2: 57.50 |
| Pivot: |
48.26 |
| Moving Average: |
MA(5): 44.25 MA(20): 49.09
MA(100): 48.51 MA(250): 33.98  |
| MACD: |
MACD(12,26): -1.91 Signal(9): -0.78 |
| Stochastic oscillator: |
%K(14,3): 22.92 %D(3): 21.71 |
| RSI: |
RSI(14): 35.22 |
| 52-week: |
High: 61.59 Low: 7.41 Change(%): 102.2 |
| Average Vol(K): |
3-Month: 432662 10-Days: 388975 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.NVTA has closed above bottom band by 2.0%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 23 Feb 2021
Invitae Outlook Remains Positive Even After Continuing Losses, Dilution - Seeking Alpha
Mon, 22 Feb 2021
Invitae Corporation (NVTA) Plunges 11.13% on February 22 - Equities.com
Wed, 17 Feb 2021
Invitae: 4Q Earnings Snapshot - San Francisco Chronicle
Wed, 17 Feb 2021
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020 - Yahoo Finance
Tue, 16 Feb 2021
Invitae Corporation (NVTA) Plunges 5.38% on February 16 - Equities.com
Mon, 15 Feb 2021
Invitae (NVTA) to Report Q4 Earnings: What's in the Offing? - Nasdaq
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. (M) |
191 |
| Shares Float (M) |
162 |
|
% Held by Insiders
|
0.90 |
|
% Held by Institutions
|
73.30 |
|
Shares Short (K)
|
30,200 |
|
Shares Short P. Month (K)
|
26,790 |
Stock Financials |
|
EPS
|
-3.900 |
|
EPS Est This Year
|
-2.350 |
|
EPS Est Next Year
|
-1.330 |
|
Book Value (p.s.)
|
3.130 |
|
Profit Margin
|
-181.19 |
|
Operating Margin
|
-142.61 |
|
Return on Assets (ttm)
|
-25.7 |
|
Return on Equity (ttm)
|
-108.4 |
|
Qtrly Rev. Growth
|
21.6 |
|
Gross Profit (p.s.)
|
0.518 |
|
Sales Per Share
|
1.288 |
|
EBITDA (p.s.)
|
-1.689 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-232 |
|
Levered Free Cash Flow (M)
|
-61 |
Stock Valuations |
|
PE Ratio
|
-10.57 |
|
PEG Ratio
|
|
|
Price to Book value
|
13.17 |
|
Price to Sales
|
32.01 |
|
Price to Cash Flow
|
-33.83 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
